Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Mark Lovell

University of Kentucky, Department: Chemistry

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Fawkes Biotechnology, LLC

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Dr. Mark Lovell and two colleagues developed an antibody-based

test, similar in appearance to a pregnancy test, which provides an indication of the

presence of and, by virtue of intensity, the severity of brain damage. The three

investigators started Fawkes Biotechnology, LLC. Fawkes Biotechnology licensed from

UK the “methods and systems for prognosis and diagnosis of brain damage”.

Listed Research Project
Validation of a Point of Care Diagnostic for Traumatic Brain Injury

Narrative Traumatic brain injury (TBI) is a substantial health care issue affecting both civilian and military populations. Despite considerable research there remains a critical need for a biomarker test that can rapidly measure a maker of mild to moderate TBI (MMTBI) in blood or cerebrospinal fluid and provide identification of patient during a clinically useful time frame. Preliminary and future studies described in this proposal aim to test the usefulness of a lateral flow device (LFD) that quantifies visinin like protein 1 (VILIP-1), a neuron specific Ca2+-sensor protein released into blood following TBI. �

Filed on October 18, 2016.

Tell us what you know about Mark Lovell's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Mark Lovell University of Kentucky Conflict of Interest Fawkes Biotechnology, LLC Value cannot be readily determined
Name Institution Type Company Disclosed Value
Mark Lovell University of Kentucky Financial Disclosure
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page